Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis

医学 贫血 肾脏疾病 透析 内科学 重症监护医学 疾病
作者
Nan Chen,Chuan‐Ming Hao,Xiaomei Peng,Hongli Lin,Aiping Yin,Hao Li,Ye Tao,Xinling Liang,Zhengrong Liu,Xing Changying,Jianghua Chen,Laimin Luo,Li Zuo,Yunhua Liao,Bi‐Cheng Liu,Robert Leong,Chunrong Wang,Cameron Liu,Thomas B. Neff,Lynda Anne M. Szczech
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:381 (11): 1001-1010 被引量:598
标识
DOI:10.1056/nejmoa1813599
摘要

BACKGROUND: Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In phase 2 studies involving patients with chronic kidney disease, roxadustat increased levels of endogenous erythropoietin to within or near the physiologic range, along with increasing hemoglobin levels and improving iron homeostasis. Additional data are needed regarding the efficacy and safety of roxadustat for the treatment of anemia in patients with chronic kidney disease who are not undergoing dialysis. METHODS: In this phase 3 trial conducted at 29 sites in China, we randomly assigned 154 patients with chronic kidney disease in a 2:1 ratio to receive roxadustat or placebo three times a week for 8 weeks in a double-blind manner. All the patients had a hemoglobin level of 7.0 to 10.0 g per deciliter at baseline. The randomized phase of the trial was followed by an 18-week open-label period in which all the patients received roxadustat; parenteral iron was withheld. The primary end point was the mean change from baseline in the hemoglobin level, averaged over weeks 7 through 9. RESULTS: During the primary-analysis period, the mean (±SD) change from baseline in the hemoglobin level was an increase of 1.9±1.2 g per deciliter in the roxadustat group and a decrease of 0.4±0.8 g per deciliter in the placebo group (P<0.001). The mean reduction from baseline in the hepcidin level (associated with greater iron availability) was 56.14±63.40 ng per milliliter in the roxadustat group and 15.10±48.06 ng per milliliter in the placebo group. The reduction from baseline in the total cholesterol level was 40.6 mg per deciliter in the roxadustat group and 7.7 mg per deciliter in the placebo group. Hyperkalemia and metabolic acidosis occurred more frequently in the roxadustat group than in the placebo group. The efficacy of roxadustat in hemoglobin correction and maintenance was maintained during the 18-week open-label period. CONCLUSIONS: In Chinese patients with chronic kidney disease who were not undergoing dialysis, those in the roxadustat group had a higher mean hemoglobin level than those in the placebo group after 8 weeks. During the 18-week open-label phase of the trial, roxadustat was associated with continued efficacy. (Funded by FibroGen and FibroGen [China] Medical Technology Development; ClinicalTrials.gov number, NCT02652819.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Merry8558完成签到,获得积分10
刚刚
刚刚
dengzx08完成签到,获得积分10
刚刚
CS发布了新的文献求助10
刚刚
陈九思完成签到,获得积分10
刚刚
刘大宝完成签到,获得积分10
刚刚
rxl发布了新的文献求助10
刚刚
搜集达人的应助被jacob258采纳,获得30
刚刚
xcy小调调完成签到 ,获得积分10
1秒前
1秒前
1秒前
NJ完成签到,获得积分10
2秒前
2秒前
Lucas的应助被健壮书包采纳,获得10
2秒前
wang完成签到,获得积分10
2秒前
从容不弱完成签到,获得积分10
2秒前
青森完成签到,获得积分10
2秒前
轻松不二完成签到,获得积分10
2秒前
Ava的应助被Hhp采纳,获得10
2秒前
JamesPei的应助被Cecilia采纳,获得10
3秒前
xiaodusb发布了新的文献求助10
3秒前
kay发布了新的文献求助10
3秒前
悦耳语堂完成签到,获得积分10
3秒前
HebingTang完成签到,获得积分10
3秒前
愉快的真发布了新的文献求助10
3秒前
zhabgyucheng完成签到,获得积分10
4秒前
4秒前
来来来发布了新的文献求助10
4秒前
害羞大雁发布了新的文献求助10
4秒前
ZHOU完成签到,获得积分10
4秒前
小y完成签到 ,获得积分10
4秒前
MYhang完成签到,获得积分10
4秒前
4秒前
肖馨余发布了新的文献求助10
5秒前
勤恳的苗条完成签到,获得积分10
5秒前
5秒前
shining完成签到,获得积分10
6秒前
6秒前
啦啦啦完成签到,获得积分20
7秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180757
求助须知:如何正确求助?哪些是违规求助? 9570857
关于积分的说明 21814590
捐赠科研通 7777053
什么是DOI,文献DOI怎么找? 3433314
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479315